EP 3814326 A4 20220316 - DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
Title (en)
DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
Title (de)
DIHYDROPYRIMIDINDERIVATE UND VERWENDUNGEN DAVON IN DER BEHANDLUNG VON HBV-INFEKTION ODER VON HBV-INDUZIERTEN ERKRANKUNGEN
Title (fr)
DÉRIVÉS DE DIHYDROPYRIMIDINE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
Publication
Application
Priority
- CN 2018092875 W 20180626
- US 201862716823 P 20180809
- CN 2019092857 W 20190625
Abstract (en)
[origin: WO2020001448A1] The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
IPC 8 full level
A61K 31/506 (2006.01); A61P 31/20 (2006.01); C07D 417/14 (2006.01)
CPC (source: EP KR)
A61K 31/506 (2013.01 - KR); A61K 45/06 (2013.01 - KR); A61P 31/20 (2017.12 - EP KR); C07D 417/14 (2013.01 - EP KR)
Citation (search report)
- [ID] WO 2014029193 A1 20140227 - SUNSHINE LAKE PHARMA CO LTD [CN]
- See references of WO 2020001448A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020001448 A1 20200102; AU 2019296117 A1 20201126; CA 3099605 A1 20200102; CN 112513017 A 20210316; EP 3814326 A1 20210505; EP 3814326 A4 20220316; JP 2021529188 A 20211028; KR 20210025596 A 20210309; MA 53023 A 20210505
DOCDB simple family (application)
CN 2019092857 W 20190625; AU 2019296117 A 20190625; CA 3099605 A 20190625; CN 201980043414 A 20190625; EP 19825897 A 20190625; JP 2020572665 A 20190625; KR 20217001605 A 20190625; MA 53023 A 20190625